Caribou Biosciences, Inc.

NASDAQ:CRBU

Biotechnology

Healthcare
$0.49 -2.74%

-$0.05 today

Market cap
$52.47M
Beta
2.33
P/E (TTM)
-1.1
EPS (TTM)
-$1.39
52W Low $1.20High $3.54

Volume 1.01M

Average 1.83M

CRBU Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Caribou Biosciences, Inc.NASDAQ: CRBU

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation declines year over year

Q1 FY2026 stock-based compensation of $2.36M fell 39.3% year over year, behind the -32.8% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 13.9% from the prior quarter. Over 3 fiscal years it compounded at +2.7% a year.

Context

  • Stock-based compensation amounted to 113.6% of revenue in FY2025, down 53.5 pp from a year earlier.
  • Stock-based compensation increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -39.3% toward the trailing-twelve-month pace of -32.8%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.36M-13.9% QoQ
Last fiscal yearDec 2025
$12.68M-24.1% YoY
LTMMar 2026
$11.16M-32.8% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-39.3%——
1 year-24.1%——
3-year CAGR+2.7%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
12.68M USD
Year-over-year change
-24.1%
4-year CAGR
+38.5%

Stock-Based Compensation vs competitors

How CRBU compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -32.8% is the 7th highest of 11, against a peer median of -10.1%.
  • Stock-based compensation amounts to 99.6% of revenue for CRBU, versus a peer median of 59.6%.
CRBU Competitors
Stock-Based Compensation for CRBU and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$33.74M USD-35.1%-23.4%—
IVAInventiva S.A.FY2025€26.77M EUR+647.7%+129.4%597.1%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$15.77M USD-32.9%-11.7%22.8%
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026$11.86M USD+7.9%+52.0%36.3%
TNYATenaya Therapeutics, Inc.LTM Mar 2026$11.51M USD-28.1%+4.4%5116.0%
CRBUCaribou Biosciences, Inc.LTM Mar 2026$11.16M USD-32.8%+2.7%99.6%
HUMAHumacyte, Inc.LTM Mar 2026$10.44M USD+45.6%+16.4%517.7%
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026$10.08M USD-60.8%-22.0%60.3%
PYXSPyxis Oncology, Inc.LTM Mar 2026$8.17M USD-33.3%-9.2%59.0%
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$7.36M USD+42.2%—26.1%
AARDAardvark Therapeutics, Inc. Common StockLTM Mar 2026$2.64M USD+336.0%+112.4%—
Peer median (excluding CRBU) —-10.1%+4.4%59.6%

Competitors are the stored peer set for CRBU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(66.92M)(99.42M)(102.07M)(149.11M)(148.13M)
Depreciation & Amortization984K3.64M3.53M3.93M3.65M
Deferred Income Tax0(95K)00(548K)
Stock-Based Compensation3.45M11.72M13.75M16.71M12.68M
Change in Working Capital29.07M(4.11M)(7.32M)(5.11M)(484K)
Accounts Receivables(2.96M)3.46M805K608K272K
Inventory00000
Accounts Payables1.14M(2.72M)1.82M(354K)3.25M
Other Working Capital30.89M(4.85M)(9.94M)(5.37M)(4.01M)
Other Non-Cash Items904K9.02M(1.18M)(4.61M)21.84M
Operating Cash Flow(32.52M)(90.97M)(93.29M)(138.2M)(110.99M)
Capital Expenditures(3.12M)(6.45M)(11.61M)(6.51M)(1.36M)
Acquisitions (Net)00000
Purchases of Investments(173.28M)(339.06M)(394.76M)(304.39M)(150.37M)
Sales of Investments0252.87M338.19M397.49M252.83M
Other Investing Activities(1M)(600K)0(1.61M)1.14M
Investing Cash Flow(176.4M)(93.25M)(68.18M)86.61M102.24M
Debt Repayment1.03M0000
Common Stock Issued321.02M2.13M152.72M15.19M4.82M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities2.55M01.58M1.53M0
Financing Cash Flow433.43M2.13M154.3M16.72M4.82M
Effect of Forex Changes00000
Net Change in Cash224.51M(182.08M)(7.18M)(34.87M)(3.93M)
Free Cash Flow(35.64M)(97.42M)(104.9M)(144.71M)(112.35M)

Caribou Biosciences, Inc.

NASDAQ:CRBU

Intrinsic Alpha fair value

Locked

Current Price

$0.49

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.